KHKen-Ichi Hirano

Ken-Ichi Hirano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ken-Ichi Hirano has a total of 247 co-authors. Here are the top co-authors by number of shared publications:

  • Yoshihiko Ikeda

    Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

    15 shared publications
  • Hideyuki Miyauchi

    Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan

    12 shared publications
  • Kunihisa Kobayashi

    Department of Endocrinology and Diabetes Mellitus, Fukuoka University Chikushi Hospital, Fukuoka, Japan

    9 shared publications
  • Tetsuya Amano

    Department of Cardiology, Aichi Medical University, Aichi, Japan

    9 shared publications
  • Satoshi Yamaguchi

    The Tochino Foundation, Osaka, Japan

    8 shared publications
  • Yusuke Nakano

    Department of Cardiology, Aichi Medical University, Aichi, Japan

    7 shared publications

Latest Publications

  • Open Access

    Triglyceride deposit cardiomyovasculopathy: A new class of cardiovascular disease

    by Tatsuya Mori, Ken-Ichi Hirano, Hideyuki Miyauchi, Yoshihiko Ikeda, Masahiro Higashi, Yusuke Nakano, Takahiro Kanda, Yasuyuki Nagasawa, Tohru Inaba, Takahiro Okumura, et al.

  • Open Access

    Interaction between fluorescently labeled BMIPP skeleton,a long-chain fatty acid analog,and CD36 forcibly expressed in HEK293 cells

    by Yasuhiro Hara, Ken-Ichi Hirano

    123I-15-(p-iodophenyl)-(R,S)-methyl pentadecanoic acid (BMIPP) is an iodine-123 labeled long-chain fatty acid (LCFA) analog that was developed to examine myocardial LCFA metabolism and has been used as a radiotracer in nuclear cardiology. However, its use is limited because of the specialized features of cardiac scintigraphy. In this study, a novel BMIPP-based probe, in which iodine-123 was replaced with a fluorescent compound, was used to evaluate the direct binding of the BMIPP-basic skeleton to CD36, an LCFA receptor. We performed fluorescence-activated cell sorting (FACS) analysis using a model cell system consisting of HEK293 cells harboring EGFP-fused CD36, and showed that the binding of the fluorescently labeled BMIPP skeleton (Alexa680-BMPP) to cells strictly correlated with CD36 expression levels and was dependent on the concentration of Alexa680-BMPP. The FACS intensities of cells bound to Alexa680-BMPP reverted to those of the control cells after incubation in non-Alexa680-BMPP medium, suggesting that Alexa680-BMPP could bind to CD36 in a reversible manner. We uniquely visualized Alexa680-BMPP bound to EGFP-fused CD36 on the cell surface using fluorescent imaging. Fluorescently labeled BMPP has the potential to be used as a probe to study the interaction between the BMIPP skeleton and CD36.

  • Long-term survival and durable recovery of heart failure in patients with triglyceride deposit cardiomyovasculopathy treated with tricaprin

    by Ken-Ichi Hirano, Satomi Okamura, Koichiro Sugimura, Hideyuki Miyauchi, Yusuke Nakano, Kotaro Nochioka, Chikako Hashimoto, Yoshitaka Iwanaga, Kenichi Nakajima, Satoshi Yamaguchi, et al.

    Heart disease is a major global threat. Triglyceride deposit cardiomyovasculopathy (TGCV) is an emerging, noncommunicable, adult-onset heart disease, first identified in Japanese patients with heart failure (HF) requiring cardiac transplantation1-3. In TGCV, defective intracellular lipolysis of long-chain triglycerides (TGs) results in cellular steatosis and energy failure mainly in cardiomyocytes4 and smooth muscle cells5, leading to HF, diffuse coronary artery disease with TG deposition and ventricular arrhythmias with high mortality6. Tricaprin, a class of medium-chain TGs, recently corrected myocardial TG lipolysis7. Here we report remarkable long-term survival and durable recovery of HF in patients with TGCV treated with supplemental tricaprin in registry studies. Our study offers a classification of heart disease caused by defective lipolysis and its possible practical treatment. Because myocardial lipid droplets are a common feature in HF and their potential as therapeutic targets has been discussed worldwide, our findings warrant investigation into other ethnicities.


  • Open Access

    Diagnostic Principle with Washout Rate of 123I-β-methyl-p-iodophenyl pentadecanoic Acid for Triglyceride Deposit Cardiomyovasculopathy

    by Ken-Ichi Hirano, Hideyuki Miyauchi, Kenichi Nakajima

    Triglyceride deposit cardiomyovasculopathy (TGCV) (Orphanet ORPHA code: 692305) is an emerging rare adult-onset cardiovascular disease, first identified in Japan. In TGCV, defective intracellular lipolysis of long-chain triglycerides (LCTGs) results in cellular steatosis and energy failure, leading to intractable heart failure, diffuse coronary artery disease, and ventricular arrhythmia. A hallmark of TGCV diagnosis is the reduced washout rate (WR) of 123I-β-methyl-p-iodophenyl pentadecanoic acid (BMIPP), a well-established radiopharmaceutical of long-chain fatty acid (LCFA). Recently, the working group of the Japanese Society of Nuclear Cardiology published the practical guideline for measuring 123I-BMIPP-WR. Here, we present the diagnostic principle of TGCV using 123I-BMIPP-WR based upon basic and clinical studies in nuclear cardiology as well as current biochemical insights into TG and LCFA metabolism.


  • Open Access

    Triglyceride Deposit Cardiomyovasculopathy Manifesting Coronary Artery Disease

    by Ken-Ichi Hirano, Yusuke Nakano, Hideyuki Miyauchi, Yoshihiko Ikeda, Masahiro Higashi, Tatsuya Mori, Takayuki Nakano, Shinichiro Fujimoto, Tomomi Yamada, Koichiro Sugimura, et al.

    Coronary artery disease (CAD) is a leading cause of death worldwide, despite the recent remarkable progress in medical and interventional remedies. Cholesterol is an established causal factor and therapeutic target for CAD; however, the role of triglyceride (TG) in atherogenesis remains unknown. Triglyceride deposit cardiomyovasculopathy (TGCV) is a novel disease concept that was first reported in patients who required cardiac transplantation in 2008. Defective intracellular lipolysis of TG results in cellular steatosis and energy failure mainly in smooth muscle cells and cardiomyocytes. Patients with TGCV exhibit unique TG-deposit atherosclerosis, with diffuse narrowing of concentric stenosis in advanced cases. These pathological characteristics are different from those of classic cholesterol-induced atherosclerosis, which shows focal and eccentric stenosis. The Japan TGCV study group developed the diagnostic criteria for TGCV, in which a low washout rate of 123I-β-methly-p-iodophenyl pentadecanoic acid in myocardial scintigraphy is an essential item. Patients with TGCV often complain of atypical cardiovascular symptoms and are resistant to cholesterol-lowering therapy and percutaneous coronary intervention with second-generation drug-eluting stents. Our recent registry study reported low 5-year overall and cardiovascular event-free survival rates in previously diagnosed patients. However, the administration of tricaprin to facilitate myocardial lipolysis of TG has been reported to regress diffuse atherosclerotic lesions in some cases of TGCV. Notably, a substantial number of patients with TGCV exist (most remain undiagnosed) in the population with acute and chronic CAD. In this review, we briefly present the disease concept, pathophysiology, diagnosis, and clinical characteristics of TGCV.


  • Open Access

    Distinct Myocardial Triglyceride Lipolysis Pathways in Primary and Idiopathic Triglyceride Deposit Cardiomyovasculopathy

    by Yoshihiko Ikeda, Mikio Shiba, Hiroyuki Yamamoto, Tomonori Itoh, Takahiro Okumura, Yusuke Nakano, Hideyuki Miyauchi, Tomomi Ide, Sohsuke Yamada, Hiroyuki Hao, et al.


  • Open Access

    Prevalence of triglyceride deposit cardiomyovasculopathy among patients with acute coronary syndrome

    by Yusuke Nakano, Ken-Ichi Hirano, Tomohiro Onishi, Hirohiko Ando, Tetsuya Amano

    Triglyceride deposit cardiomyovasculopathy (TGCV) is an emerging cardiovascular disorder exhibiting diffuse narrowing of the coronary arteries due to defective intracellular lipolysis of triglyceride (TG). It is associated with a high risk of major cardiovascular events. However, many patients may remain undiagnosed due to limited awareness of the disease and the necessity for specific diagnostic tests that indicate TG accumulation in the myocardium.1–4 Given that coronary artery disease (CAD) is a leading cause of death worldwide, determining the frequency of TGCV and stratifying it as a risk factor for CAD is crucial. However, no real-world data exist regarding the prevalence of TGCV among patients with common cardiovascular diseases. Therefore, we conducted a retrospective study to evaluate the prevalence of TGCV among patients with common cardiovascular diseases presenting as acute coronary syndrome (ACS).


  • Open Access

    Correction: Practice recommendation for measuring washout rates in 123I-BMIPP fatty acid images

    by Kenichi Nakajima, Hideyuki Miyauchi, Ken-Ichi Hirano, Shinichiro Fujimoto, Michitomo Kawahito, Takashi Iimori, Takashi Kudo

  • Open Access

    Overall Survival Rate of Patients With Triglyceride Deposit Cardiomyovasculopathy

    by Ken-Ichi Hirano, Hideyuki Miyauchi, Yusuke Nakano, Yuko Kawaguchi, Satomi Okamura, Yuki Nishimura, Tomohiro Onishi, Shinichiro Fujimoto, Tomomi Yamada, Tetsuya Amano


  • Open Access

    Carnitine Administration and 123I-BMIPP Washout Rate in Hemodialysis Patients with Triglyceride Deposit Cardiomyovasculopathy

    by Ken-Ichi Hirano, Keita Kodama, Hideyuki Miyauchi, Yasuyuki Nagasawa, Yusuke Nakano, Masaki Matsunaga, Tetsuya Amano, Kenichi Nakajima

    Triglyceride deposit cardiomyovasculopathy (TGCV) is an emerging rare heart disease with high mortality, characterized by defective intracellular lipolysis of triglycerides (TG). We developed diagnostic criteria for TGCV, in which low washout rate of BMIPP (BMIPP-WR) is a key factor. The working group of the Japan Society of Nuclear Cardiology recently published practice recommendations for measuring BMIPP-WR. We reported that hemodialysis (HD) patients with TGCV exhibited a markedly higher cardiovascular risk than those without TGCV. Secondary carnitine deficiency is common in patients undergoing HD, as carnitine is removed from the circulation. However, clinical evidence linking carnitine levels to BMIPP-WR is limited. Here we report the effect of L-carnitine administration on the BMIPP-WR in 9 chronic HD patients with TGCV in a retrospective cohort. The mean age at TGCV diagnosis was 59 years. Following standard doses of oral L-carnitine administration, plasma free carnitine levels significantly increased. However, BMIPP-WR was not changed. In normal condition, most BMIPP taken up were esterified/incorporated into TG pool, hydrolyzed by intracellular lipases, and then transported by carnitine shuttle to mitochondria. In TGCV, intracellular TG lipolysis is defective. During the intracellular metabolism of BMIPP, carnitine shuttling occurs downstream of TG lipolysis. Therefore, even when carnitine levels were increased, BMIPP-WR did not change in patients with TGCV who underwent chronic HD. A phase IIb/III clinical trial for TGCV, is underway (jRCT2051210177). Increased awareness of the disease concept of TGCV, along with its diagnostic principles and procedures using BMIPP scintigraphy, is warranted.